Vilitra

Vilitra, containing the active ingredient Vardenafil, is a prescription medication specifically formulated for the treatment of erectile dysfunction (ED). As a phosphodiesterase type 5 (PDE5) inhibitor, it operates by enhancing blood flow to the penile tissues, facilitating the achievement and maintenance of an erection sufficient for sexual activity. This medication is recognized for its reliable efficacy and rapid onset of action, making it a trusted choice among healthcare providers for managing this common condition. Proper diagnosis and adherence to medical guidance are essential for optimal therapeutic outcomes.

Features

• Active ingredient: Vardenafil (available in 10mg, 20mg, and 40mg strengths)
• Mechanism of action: Selective inhibition of phosphodiesterase type 5 (PDE5)
• Onset of action: Typically within 25-60 minutes post-administration
• Duration of effect: Up to 4-5 hours
• Administration: Oral tablet, taken with or without food (though high-fat meals may delay absorption)
• Manufacturer compliance: Produced under strict Good Manufacturing Practice (GMP) standards

Benefits

• Facilitates reliable erectile function by improving nitric oxide-mediated vasodilation in the corpus cavernosum.
• Offers a favorable pharmacokinetic profile with a rapid onset, allowing for spontaneity in sexual activity.
• Provides sustained efficacy throughout the therapeutic window, supporting satisfactory sexual performance.
• Supported by extensive clinical data demonstrating significant improvement in International Index of Erectile Function (IIEF) scores.
• Enhances patient confidence and quality of life by effectively addressing the physiological aspects of ED.
• Available in multiple dosages, allowing for individualized titration under medical supervision.

Common use

Vilitra (Vardenafil) is primarily indicated for the management of erectile dysfunction in adult males. It is used in cases where there is an inability to achieve or maintain an erection sufficient for satisfactory sexual performance. The medication is suitable for a broad range of ED etiologies, including vasculogenic, neurogenic, and psychogenic origins, though a thorough medical evaluation is necessary to determine appropriateness. It is not intended for use in women, pediatric populations, or individuals without erectile dysfunction.

Dosage and direction

The recommended starting dose of Vilitra is 10mg, taken approximately 25-60 minutes prior to anticipated sexual activity. Based on efficacy and tolerability, the dose may be titrated upward to 20mg or reduced to 5mg. The maximum recommended dosage is 20mg per 24-hour period. Administration may occur with or without food; however, high-fat meals can delay absorption and time to onset. Sexual stimulation is required for the medication to be effective. Do not exceed prescribed dosing frequency.

Precautions

Prior to initiating Vilitra, a comprehensive cardiovascular assessment is recommended due to the potential cardiac risk associated with sexual activity. Use with caution in patients with anatomical deformation of the penis, predisposition to priapism, bleeding disorders, or active peptic ulceration. hepatic impairment necessitates dose adjustment—avoid use in severe hepatic impairment. Renal impairment (CrCl <30 mL/min) warrants careful dose initiation at 5mg. Vilitra may cause hypotension; caution is advised in patients on antihypertensive therapy.

Contraindications

Vilitra is contraindicated in patients with a known hypersensitivity to Vardenafil or any excipients in the formulation. Concomitant use with organic nitrates or nitric oxide donors in any form is strictly prohibited due to the risk of profound hypotension. It is also contraindicated in patients taking guanylate cyclase stimulators such as riociguat. Use is not recommended in individuals with severe hepatic impairment, hypotension (BP <90/50 mmHg), recent stroke or myocardial infarction, or unstable angina.

Possible side effects

Common adverse reactions include headache, flushing, dyspepsia, nasal congestion, and dizziness. Less frequently, patients may experience blurred vision, altered color perception, back pain, or myalgia. Priapism (prolonged and painful erection lasting more than 4 hours) is a rare but serious side effect requiring immediate medical intervention to prevent permanent tissue damage. Sudden hearing loss or non-arteritic anterior ischemic optic neuropathy (NAION) have been reported in association with PDE5 inhibitor use, though causality is not firmly established.

Drug interaction

Vilitra is primarily metabolized by CYP3A4 enzymes. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir) necessitates a maximum dose of 5mg in a 24-hour period. Moderate inhibitors (e.g., erythromycin) may require dose reduction. Alpha-blockers (e.g., doxazosin) may potentiate hypotensive effects—concomitant use should be avoided or initiated only under close medical supervision. Avoid concurrent administration with other PDE5 inhibitors. Grapefruit juice may increase Vardenafil plasma concentrations and should be avoided.

Missed dose

Vilitra is prescribed for use on an as-needed basis rather than a scheduled regimen; therefore, the concept of a “missed dose” does not apply. It should only be taken prior to anticipated sexual activity, with a maximum of one dose per 24-hour period. Do not take extra tablets to make up for a missed opportunity for intercourse.

Overdose

In cases of suspected overdose, standard supportive measures should be employed. Expected manifestations may mirror dose-related adverse effects, including severe headache, hypotension, syncope, and prolonged erection. Priapism requires urgent urological intervention. Hemodialysis is not expected to significantly accelerate elimination due to high protein binding and extensive tissue distribution. Contact a poison control center or seek emergency medical attention immediately.

Storage

Store Vilitra tablets at room temperature (15-30°C or 59-86°F), in a tightly closed container, and protect from light and moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly discard any unused or expired medication in accordance with local guidelines, avoiding flushing or disposal in household trash where possible.

Disclaimer

This information is intended for educational purposes only and does not constitute medical advice. Vilitra is a prescription medication and should only be used under the direction of a qualified healthcare professional. Individual results may vary. Always consult with a physician for diagnosis and treatment recommendations tailored to your specific health status and needs. Do not initiate, discontinue, or change the dosage of any medication without professional medical supervision.

Reviews

Clinical studies and post-marketing surveillance indicate high patient satisfaction with Vilitra, noting its rapid onset and consistent performance. Many users report significant improvement in erectile function and overall sexual satisfaction. Healthcare providers often highlight its favorable efficacy and safety profile when used appropriately in indicated populations. As with all pharmacological agents, individual experiences may vary, and adherence to prescribing information is paramount.